A great piece in the Financial Times this week “How Alderley Park Grew into an Innovation Hub” which highlights the success of Alderley Park following AstraZeneca’s announced departure 5 years ago. Ned Wakeman talks about his team’s continued support of the start-up companies and Dr Chris Doherty explains the vision of the site that will continue to build upon the strong life science legacy. Professor Ruth Roberts of ApconiX, Dr Steve McConchie of Aptus and Professor Paul Stott of Seda Pharmaceutical Development Services all discuss the importance of community and collaboration – and the drive provided by the talented individuals who chose not to move down to Cambridge but instead stayed, creating the many successful companies who now form part of the vibrant hub at Alderley Park in Cheshire. The Financial Times has an online subscription model. Search for “North takes on South in UK’s life science industry”.
About the Author: Ruth Roberts
Professor Ruth A Roberts, PhD, ATS, FBTS, ERT, FRSB, FRCPath. A co-founder of ApconiX, Ruth has 25 years of experience in leading roles in drug safety within large pharma. Ruth is also Chair and Director of Drug Discovery at The University of Birmingham, UK and was previously Global Head of Regulatory Safety at AstraZeneca. With over 140 publications in peer-reviewed journals, she is former president of the British Toxicology Society, former president of EUROTOX, former secretary to SOT and President of the Academy of Toxicological Sciences. Ruth was the recipient of the SOT Achievement award in 2002, the EUROTOX Bo Holmstedt Award in 2009 and the SOT Founders award in 2018 for outstanding leadership in toxicology. Ruth is an established science professional bringing rigorous expert thinking to toxicology, drug discovery and drug development.
